与肥胖性肝病相关的代谢功能障碍:一篇评论
Janna Vanessa Diaz Torres1, Vanessa Rocío Villanueva Guerrero1, Jennifer Patricia Vargas Gómez1
1Internal Medicine Program, Faculty Of Health, Exact And Natural Sciences, Universidad Libre, Barranquilla, Colombia.
与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一种普遍的疾病,影响全球超过三分之一的人口,特别是那些患有肥胖的人. 本综述详细介绍了MASLD的新命名,诊断和治疗方法.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢障碍 代谢障碍 代谢障碍
- 临床医学 临床医学
背景情况:
- 代谢功能障碍相关的脂肪性肝病 (MASLD) 取代了非酒精性脂肪性肝病,强调其与代谢问题的联系.
- MASLD的特点是肝硬化和代谢风险因素,如2型糖尿病和肥胖.
- 它影响全球超过33%的人口,在男性中更为常见.
研究的目的:
- 提供MASLD.的全面临床概述.
- 为了解释从NAFLD到MASLD的名称的变化.
- 为了让读者熟悉MASLD的诊断和治疗.
主要方法:
- 关于MASLD的当前文献的综述.
- 讨论诊断成像 (弹性成像,MRI) 和生物标志物.
- 分析治疗策略,包括改变生活方式和新兴疗法.
主要成果:
- MASLD是一种复杂的疾病,受到环境,遗传和表观遗传因素的影响.
- 准确的诊断涉及成像和血清学标记,弹性图像和MRI是纤维化评估的关键.
- 生活方式的改变,包括饮食和运动,是主要的治疗方法,有望的药理选择正在研究中.
结论:
- 转向MASLD术语的目的是减少耻辱和更好地定义这种情况.
- 早期诊断和干预,专注于代谢健康,对于管理MASLD至关重要.
- 对药理疗法的持续研究为改善患者治疗结果提供了希望.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
07:12Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
Published on: June 2, 2023
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
